Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis
Karagiannis T, Avgerinos I, Liakos A, et al.
Diabetologia. Pub. online 17 May 2022.
Leggi
Le Breaking News di colore blu sono relative ad abstract di articoli originali di particolare rilevanza.
Karagiannis T, Avgerinos I, Liakos A, et al.
Diabetologia. Pub. online 17 May 2022.
Leggi
Marfil-Garza BA, Imes S, Verhoeff K, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00114-0.
Leggi
Schwartz AV, Backlund JYC, de Boer IH, et al.
Lancet Diabetes Endocrinol. 2022;S2213-8587(22)00103-6.
Leggi
Bundgaard J, Mogensen UM, Christensen S et al
NMCD. Pub. online 19 May 2022
Leggi
Nimri R, Marianna R, Yackobovitch-Gavan M, et al.
J Clin Endocrinol Metab. 2022;dgac288. Pub. online 7 May 2022.
Leggi
Han E, Han Kd, Lee BW, et al.
J Clin Endocrinol Metab. 2022;107(5):e1976-e1986.
Leggi
Coll JC, Garceau E, Leslie WD, et al.
J Clin Endocrinol Metab. 2022;107(5):e1860-e1870.
Leggi
Kelsey MD, Nelson AJ, Green JB, et al.
J Am Coll Cardiol. 2022;79(18):1849-57.
Leggi
He L, Wang J, Ping F, et al.
JAMA Intern Med. 2022;182(5):513-9.
Leggi
Zaccara TA, Paganoti CF, Mikami FCF, et al.
BMC Pregnancy and Childbirth 2022;22:385.
Leggi